Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
 

1: Peer Exchange: SPR1NT Trial of Onasemnogene Abeparvovec for SMA

The SPR1NT phase 3 clinical trial—pivotal in pushing the concept of newborn screening for SMA—assessing onasemnogene abeparvovec-xioi in children less than 6 weeks of age is discussed, as well as a recently released integrated safety report.
 
 

2: Progressive MS: The CMSC 2020 Whitaker Lecture

Scott Newsome, DO, MSCS, FAAN, president of CMSC, offers his perspective on the 2020 Whitaker Lecture from Peter Calabresi, MD.
 
 

3: AHS 2020: Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.
 
 

4: Insights: Gastroparesis and Uptake of Oral Medication for Parkinson Disease

Peter LeWitt, MD, offers an expert perspective on gastroparesis and its influence on the uptake of oral medication for Parkinson disease.
 
 

5: Intranasal DHE Meets Primary Objectives in Treatment of Acute Migraine

Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.